Montelukast + Placebo
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Upper Respiratory Infection
Conditions
Upper Respiratory Infection
Trial Timeline
Oct 1, 2003 → Jul 1, 2007
NCT ID
NCT00189475About Montelukast + Placebo
Montelukast + Placebo is a approved stage product being developed by Merck for Upper Respiratory Infection. The current trial status is completed. This product is registered under clinical trial identifier NCT00189475. Target conditions include Upper Respiratory Infection.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00599534 | Phase 2 | Withdrawn |
| NCT00406094 | Approved | UNKNOWN |
| NCT00189462 | Approved | Completed |
| NCT00189475 | Approved | Completed |
| NCT00590772 | Approved | Completed |
| NCT01011452 | Approved | Completed |
Competing Products
20 competing products in Upper Respiratory Infection